OLX501A / OliX Pharma - LARVOL DELTA

The ALK7-targeting obesity therapy "OLX501A" is preparing nonclinical and clinical entry with a goal of submitting a phase 1 IND in the first half of next year. (Chosun Biz)

New P1 trial • Obesity

OliX’s OLX501A Demonstrates Greater Visceral Fat Reduction Relative to a Global Comparator in Obese Non-Human Primates (Businesswire) - "At Day 49, MRI analysis showed that after adjustment for baseline values and food intake, visceral fat volume in the OLX501A group was reduced by 29.2%. Under the same conditions, the comparator group showed a 10.0% reduction, while visceral fat increased by 11.1% in the control group over the study period. These findings suggest a differentiated effect of OLX501A on visceral fat reduction in this study setting...At Day 70, ALK7 mRNA knockdown measured in subcutaneous adipose tissue reached approximately 90% in the OLX501A group, a level generally comparable to that observed with the comparator....Based on these data, we believe OLX501A may offer a differentiated profile, and we plan to continue advancing the program toward submission of a clinical trial application in the first half of 2027."

New trial • Preclinical • Obesity

Daeshin Securities announced on June 23rd that OliX Pharmaceuticals (KOSDAQ: 226950) is broadening its therapeutic ambitions… (KBI Intelligence) - "Phase 1 trials have concluded, and OliX expects to receive the clinical study report (CSR) between August and October. Phase 2 enrolment and the associated milestone payments from Eli Lilly are then anticipated to follow...OLX501A, has produced encouraging early results. In a single-dose primate study, it reduced target messenger RNA by as much as 84%. More strikingly, when combined with tirzepatide (sold as Zepbound) at just one-tenth of the standard high dose, the drug maintained its fat-reduction effect while also blunting the weight rebound typically seen after treatment is stopped...Full data are scheduled to be disclosed at an R&D day on July 14th. The company is seeking to license the asset to a partner before initiating clinical trials....OliX is advancing a treatment for age-related macular degeneration, OLX301A...company plans to file an investigational new drug (IND) application for a multi-country phase 2 trial in the second half of this year..."

IND • New P2 trial • P1 data • Preclinical • Trial status • Age-related Macular Degeneration • Metabolic Dysfunction-Associated Steatohepatitis • Obesity